Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Articles
Data Insights
Vantage Data Points
Share Price Movers July 2019
August 06, 2019
Share price movers – July 2019
Edwin Elmhirst
Vantage Data Points
Related Companies
Achillion Pharmaceuticals
Amneal Pharmaceuticals
Lexicon Pharmaceuticals
Marinus Pharmaceuticals
Mezzion Pharma
scPharmaceuticals
Silence Therapeutics
Spexis
Vivesto
Download PDF
Share This Article
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Related Articles
April 04, 2011
Pharmasset the stand out small cap performer in first quarter
September 29, 2022
Go or no go? GSK takes its turn with a novel anaemia class
July 13, 2022
Few biopharma risers stand out at the half year
March 02, 2022
US FDA approval tracker: February 2022
February 25, 2022
Go or no go? Bristol’s Lag3 debut
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics
